Monitor upcoming Q1 2026 earnings for confirmation of the $744 million IPR&D expense and final EPS results; the updated guidance range implies slightly lower profitability expectations for the year.
Price Chart
Executive Summary
AbbVie updated its 2026 adjusted diluted EPS guidance to $13.96–$14.16, incorporating a $0.41 per share impact from Q1 2026 acquired IPR&D and milestones expense. This follows the company's prior full-year guidance of $14.37–$14.57, which excluded such expenses.
Key Facts
- AbbVie issued updated 2026 full-year adjusted diluted EPS guidance of $13.96–$14.16, down from prior range of $14.37–$14.57
- The reduction reflects a $0.41 per share impact from acquired IPR&D and milestones expense incurred in Q1 2026
- The company does not forecast future IPR&D or milestones expenses due to uncertainty in timing and occurrence
- This filing provides preliminary estimates; final results are subject to closing procedures
Financial Impact
Full-year adjusted EPS guidance reduced by $0.41 to $13.96–$14.16, reflecting $744 million in Q1 2026 acquired IPR&D and milestones expense
Risk Factors
- Future IPR&D and milestones expenses remain uncertain and could further impact earnings
- Preliminary estimates are subject to change upon final financial closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000011 |
| Document: abbv-20260331nonxgaapxex991.htm | 0001551152-26-000011 |
| Document: 0001551152-26-000011-index-headers.html | 0001551152-26-000011 |
| Document: 0001551152-26-000011-index.html | 0001551152-26-000011 |
| Document: 0001551152-26-000011.txt | 0001551152-26-000011 |
| 8-K Data (Synthetic) | 0001551152-26-000011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Court Ruling | $261.77 $264.48 | ▲ +1.04% | ▼ −0.62% | $260.37 (−0.53%) |
Sep 3, 2026 29d ago | 8-K | $260.21 $257.12 | ▼ −1.19% | ▼ −0.04% | $260.37 (+0.06%) |
Aug 5, 2026 8w ago | 8-K | $243.87 $250.82 | ▲ +2.85% | ▲ +1.64% | $260.37 (+6.77%) |
Aug 3, 2026 8w ago | Institutional Cluster | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $260.37 (+6.23%) |
Aug 3, 2026 8w ago | Court Ruling | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $260.37 (+6.23%) |
Jul 31, 2026 9w ago | 8-K | $250.94 $246.04 | ▼ −1.95% | ▼ −5.46% | $260.37 (+3.76%) |
Jul 27, 2026 9w ago | Court Ruling | $256.91 $250.94 | ▼ −2.32% | ▼ −3.40% | $260.37 (+1.35%) |
Jun 22, 2026 14w ago | 8-K | $230.01 $254.31 | ▲ +10.56% | ▲ +11.02% | $260.37 (+13.20%) |
May 18, 2026 19w ago | Court Ruling | $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $260.37 (+24.34%) |
Apr 29, 2026 22w ago | 8-K | $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $260.37 (+27.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access